OTC Probiotics Face Challenging Regulatory Framework
This article was originally published in The Tan Sheet
Executive Summary
The development of OTC drugs based on probiotics requires a regulatory system more receptive to research on the microorganisms' use as therapeutic ingredients, according to microbiologist Gary Huffnagle.
You may also be interested in...
J&J’s Problems, Pfizer’s Options And Switch Outlook Top “The Tan Sheet” Topics In 2011
Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.
J&J’s Problems, Pfizer’s Options And Switch Outlook Top “The Tan Sheet” Topics In 2011
Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.
Health Canada Responds To Probiotics Proliferation With Revised Regulation
Canada’s evolving regulatory framework for probiotics may offer lessons for the U.S., though statutes constrain how much FDA can change.